Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betamethasone dipropionate + urea is a topical combination medication used to treat inflammatory skin conditions such as eczema (atopic dermatitis) and psoriasis. Betamethasone dipropionate is a potent synthetic glucocorticoid corticosteroid that acts as an anti-inflammatory and immunosuppressive agent, reducing redness, swelling, and itching by inhibiting the production of pro-inflammatory mediators in the skin. Urea serves as a keratolytic agent, helping to remove dead tissue and enhance skin hydration, which accelerates healing and improves penetration of the corticosteroid. This combination is intended for external use only on affected areas of the skin[6]. It should be used with caution in certain populations (e.g., children under 13 years old, pregnant or breastfeeding women), and common side effects include local irritation such as redness or burning at the application site[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone dipropionate + urea.